Brain Trust: Conversations in Psychopharmacology

Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.

Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.

Learn how to spot and treat sexual dysfunction in psychiatric care—screen causes, manage SSRI effects, and choose libido-friendly medications.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

Experts weigh benzodiazepine benefits, dependence myths, and safer prescribing in older adults, including what evidence really says about Alzheimer risk.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

Experts unpack when benzodiazepines help or harm, tapering myths, older-adult risks, and why Alzheimer links may be overstated.

Learn how clinicians reframe side effects, curb nocebo, and boost outcomes using expectation, open-label placebos, and conditioning in psychiatry.

Experts discuss the impact of the placebo effect on psychiatric treatment outcomes.

Placebo and nocebo effects shape psychiatric care—how expectations and framing boost medication benefit and reduce side effects.

Experts unpack placebo and nocebo effects in psychiatry, revealing how expectation, framing, and alliance boost outcomes and curb side effects.

Learn how clinicians tackle mood and substance use disorders together, boost patient engagement, and expand evidence-based addiction medications for bipolar and alcohol use.

AI is reshaping psychopharmacology—from TRD prediction to digital phenotyping—while exposing data limits, workflow hurdles, and safety risks in suicide tools.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Explore how to manage mood and substance use disorders together, boost engagement, and expand addiction medications.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

David Dunner, MD, FACPsych, reveals insights into rapid cycling roots, bipolar II, and weighing lithium as an often overlooked treatment option.

Experts reveal why psych medication nonadherence is common, how to discuss it without blame, and tools like CAE and injectables to prevent relapse.

Experts unpack why most psychiatric care relies on off‑label meds, how neuroscience guides safe polypharmacy, and what could reshape FDA approvals.

How AI can aid everyday psychiatry—TRD prediction, suicide risk, and smartphone phenotyping—plus why data quality and workflow still block adoption.

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.

Experts explain how careful pediatric psychopharmacology and early intervention protect development, curb relapse, and address substance-use risk.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

Explore psychopharmacologic options for personality disorders in this podcast.

Psychiatry leaders unpack pharmacogenetic testing hype, spotlight 4 actionable genes, and urge evidence-based use with therapeutic drug monitoring for personalized treatment.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.